Physician

Mukesh Gopalakrishnan, M.D.

According to 2025 Medicare claims, Mukesh Gopalakrishnan, M.D. (NPI: 1326350562) practices interventional cardiology in the Tucson, AZ market, with the plurality of this provider's patient population coming from Pima, AZ. This provider's primary affiliated billing organization is PIMA HEART PHYSICIANS, PC (NPI: 1730137480; TIN: 860888560) and primary practice location at 85614-6336. Gopalakrishnan is affiliated with the P3 Health Partners REACH ACO LLC (ACO ID: D0327), participating under the REACH model.

Gopalakrishnan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,962 traditional Medicare patients, billed 15,112 HCPCS/CPT codes, and received $983,142 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 15,171 prescription claims across 2,124 beneficiaries totaling $2,913,041 in drug costs, led by Eliquis (Apixaban). DME data shows 66 claims. Open Payments data shows 49 records totaling $954. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,871 to $2,913,041. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $37,077 to $10,110.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	465	1,559	$140,934
2018	1,649	8,844	$845,314
2019	1,839	10,449	$1,003,196
2020	1,851	10,950	$1,025,810
2021	1,915	11,555	$1,186,700
2022	1,916	20,130	$1,261,554
2023	1,917	18,372	$934,463
2024	1,962	15,112	$983,142

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	13	44	$3,871
2016	28	78	$3,249
2017	233	674	$39,329
2018	1,083	6,509	$703,305
2019	1,349	10,192	$1,381,607
2020	1,500	11,752	$1,712,227
2021	1,681	12,649	$2,034,242
2022	1,843	13,065	$2,235,754
2023	2,002	14,789	$2,717,994
2024	2,124	15,171	$2,913,041

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	19	$37,077
2019	N/R	16	$548
2020	69	237	$7,563
2021	74	173	$5,450
2022	22	161	$4,754
2023	N/R	88	$3,062
2024	N/R	66	$1,942

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	257	257	$117
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	553	560	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,370	2,491	$91
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	1,282	1,768	$10
J2785	Injection, regadenoson, 0.1 mg	206	824	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	1,163	67,031	$1,293,104
Entresto	Sacubitril/Valsartan	431	22,700	$477,919
Xarelto	Rivaroxaban	306	20,131	$369,517
Jardiance	Empagliflozin	182	10,320	$203,495
Farxiga	Dapagliflozin Propanediol	98	5,684	$103,860

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A7034	Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap	N	N/R	16	$793
A4604	Tubing with integrated heating element for use with positive airway pressure device	N	N/R	21	$775
A7038	Filter, disposable, used with positive airway pressure device	N	N/R	16	$189
A7035	Headgear used with positive airway pressure device	N	N/R	13	$185

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	49	$954	ABIOMED
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mukesh Gopalakrishnan, M.D.?

Tedicare shows public-source Medicare data for Mukesh Gopalakrishnan, M.D. (NPI 1326350562), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mukesh Gopalakrishnan, M.D. have ACO affiliation data?

Mukesh Gopalakrishnan, M.D. is shown with ACO affiliation data for P3 Health Partners REACH ACO LLC (REACH, ACO ID D0327).

What billing organization is linked to Mukesh Gopalakrishnan, M.D.?

Mukesh Gopalakrishnan, M.D. is linked to PIMA HEART PHYSICIANS, PC (billing NPI 1730137480) in the available physician profile data.

Does Mukesh Gopalakrishnan, M.D. have Open Payments data?

Mukesh Gopalakrishnan, M.D. has 49 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.